Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation
2008-008554-23Phase 4Completed
- Sponsor
- The Multiple Sclerosis Research Group, Department of Clinical Neuroscience
- Start
- Jun 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by The Multiple Sclerosis Research Group, Department of Clinical Neuroscience. Primary endpoint: Development of neutralizing antibodies (NAb) to interferon beta. Started Jun 2009; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-008554-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008554-23.